Central Florida Pulmonary Group

1. Vertex Pharmaceuticals Incorporated $210,505 11 payments
2. Chiesi USA, Inc. $210,250 39 payments
3. Insmed, Inc. $101,781 178 payments
4. Paratek Pharmaceuticals, Inc. $13,333 4 payments
5. RedHill Biopharma Inc. $7,200 2 payments
6. Actelion Pharmaceuticals, Ltd $3,600 3 payments
7. Amgen Inc. $2,000 1 payment
8. Allergan Inc. $1,929 3 payments
9. Pfizer Inc. $1,339 1 payment
10. VIVUS, Inc. $1,053 3 payments

1. A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) $116,633 27 payments
2. A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (Triton) $93,617 12 payments
3. A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy $86,507 1 payment
4. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study $63,591 157 payments
5. A Phase 2, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis $45,311 1 payment
6. A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes) $25,497 1 payment
7. A Phase 2, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease $22,475 8 payments
8. A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF) $17,964 1 payment
9. A Phase 1 Study of VX-814 $14,274 1 payment
10. A Phase 2, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Omadacycline in Adult Subjects with Nontuberculous Mycobacterial Pulmonary Disease Caused by Mycobacterium abscessus complex $13,333 4 payments

1. Other $1,053 3 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.